Ed DeVaney’s promotion is the latest leadership shakeup at CVS Health as the company works on a multi-year turnaround plan.
Argus raised the firm’s price target on CVS Health (CVS) to $77 from $68 and keeps a Buy rating on the shares. Despite an uneven performance ...
In a report released on February 14, Steven Silver from Argus Research maintained a Buy rating on CVS Health (CVS – Research Report). The ...
There’s strong opposition to the upcoming closure of a CVS in downtown Hartford, the only drug store in that area. An online ...
We recently compiled a list of the 10 Best Performing S&P 500 Stocks So Far in 2025. In this article, we are going to take a look at where CVS Health Corporation (NYSE:CVS) stands against the other ...
Stock futures slipped Friday morning. GameStop could soon be getting into the cryptocurrency space. Trump has signed his anticipated "reciprocal tariffs" plan on foreign nations.